EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial

Michiel Rienstra iD, Anderson C Woite-Silva iD, Aaf Kuijper iD, Sabine Eijsbouts iD, Karin Kraaier, Tomas Janota, Clara Van Ofwegen iD, Ype Tuininga, Erik Badings iD, Jose Luis Merino iD, Jeremy N Ruskin iD, A John Camm und 5 weitere

Europace · 2025

DOI: 10.1093/europace/euaf064 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Michiel Rienstra und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Hauptthemen laut MEDLINE: Atrial Fibrillation, Flecainide, Anti-Arrhythmia Agents, Heart Rate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: InCarda Therapeutics Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. New treatments are needed to cardiovert recent-onset paroxysmal AF quickly and safely. RESTORE-1 was a multicentre, randomized, double-blind, placebo-controlled trial of a 120 mg orally inhaled solution of flecainide acetate (FlecIH-103) for cardioversion of symptomatic, recent-onset (≤48 h) paroxysmal AF. The study aim was to evaluate the efficacy and safety of FlecIH-103 administered via oral inhalation. Methods and results Patients experiencing a recent-onset paroxysmal AF episode were randomized to receive a single dose of FlecIH-103 or placebo delivered over two 3.5 min inhalation periods, while patients were monitored using 12-lead electrocardiograms and Holter. The trial was stopped prematurely after treating 55 patients, due to lower-than-expected conversion rates and plasma levels. Mean age was 59.6 years, 31.5% of patients were female, and 59.2% were having their first AF episode. Conversion rate was 30.8% (95% confidence interval: 14.7–43.8) for the active group (n = 39) and 0.0% for the placebo group (n = 12) (P = 0.04). Median time to conversion was 12.8 min (IQR: 17.2). In the active group, the mean flecainide plasma level was 198 ng/mL (SD: 156), which is ∼50% lower than in the previous studies. The most common adverse events (AEs) were dysgeusia, dyspnoea, and cough. All AEs were short-lasting and of mild or moderate intensity.

Conclusion

Despite early termination of the trial, FlecIH-103 was significantly more effective than placebo in cardioverting AF. Safety data did not show any serious AEs. Further studies of FlecIH-103 are needed to optimize the combination of drug formulation and inhalation delivery platform. Clinical trial registration URL: https://clinicaltrials.gov, unique identifier: NCT05039359

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationFlecainideAnti-Arrhythmia AgentsHeart RateHumansFemaleMaleMiddle AgedDouble-Blind MethodAdministration, InhalationTreatment OutcomeAgedTime FactorsElectrocardiography, AmbulatoryEarly Termination of Clinical Trials

Stichwörter der Autor:innen

Atrial fibrillationCardioversionFlecainideOral inhalation

Substanzen

FlecainideAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
  • InCarda Therapeutics, Newark, CA, USA.
  • Department of Cardiology, Spaarne Gasthuis, Haarlem, The Netherlands.
  • Department of Cardiology, Maxima Medical Center, Veldhoven, The Netherlands.
  • Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
  • Department of Cardiology, General University Hospital, Prague, Czechia.

ORCID-Profile: Michiel Rienstra, Anderson C Woite-Silva, Aaf Kuijper, Sabine Eijsbouts, Clara Van Ofwegen, Erik Badings, Jose Luis Merino, Jeremy N Ruskin, Peter R Kowey, Jean Maupas

Förderung

  • InCarda Therapeutics Inc

Zitieren

APA

Rienstra, M., Woite-Silva, A. C., Kuijper, A., Eijsbouts, S., Kraaier, K., Janota, T., Van Ofwegen, C., Tuininga, Y., Badings, E., Merino, J. L., Ruskin, J. N., Camm, A. J., Kowey, P. R., Dufton, C., Maupas, J., Parsell, D., & Belardinelli, L. (2025). Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. Europace. https://doi.org/10.1093/europace/euaf064

Vancouver

Rienstra M, Woite-Silva AC, Kuijper A, Eijsbouts S, Kraaier K, Janota T, et al. Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. Europace. 2025. doi:10.1093/europace/euaf064

BibTeX
@article{Rienstra2025,
  author = {Rienstra, Michiel and Woite-Silva, Anderson C and Kuijper, Aaf and Eijsbouts, Sabine and Kraaier, Karin and Janota, Tomas and Van Ofwegen, Clara and Tuininga, Ype and Badings, Erik and Merino, Jose Luis and Ruskin, Jeremy N and Camm, A John and Kowey, Peter R and Dufton, Christopher and Maupas, Jean and Parsell, Dawn and Belardinelli, Luiz},
  title = {Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf064}
}
Kostenlos starten →